DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for GM1 gangliosidosis type 1 — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleGM1 gangliosidosis type 1 maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for gm1 gangliosidosis type 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
galactosidase beta 1 (GLB1) — GLB1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2r,3s,4r,5sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3THD · 1.79 Å · ligand (2R,3S,4R,5S)-2-(hydroxymethyl)piperidine-3,4,5-triol (DGJ). Experimental structure, not a prediction.
What the evidence adds up to
GM1 gangliosidosis type 1 is a progressive neurodegenerative disease caused by GLB1 gene mutation leading to deficiency of the lysosomal enzyme β-galactosidase and accumulation of GM1 ganglioside in the central nervous system. In the most severe early infantile phenotype, death occurs within 2 years of age. A single-centre retrospective study of 14 patients followed between 1988 and 2021 reported median survival less than 24 months, and found that β-galactosidase enzyme activity may be associated with clinical onset and time of diagnosis. One case report describes a 9-month-old male with type 1 GM1 gangliosidosis who had extensive Mongolian spots present since birth, before other disease features appeared. An earlier case report from 1987 describes a typical case with all main clinical and biological signs, diagnosis confirmed by severe β-galactosidase deficiency in leucocytes and urinary oligosaccharides, with fatal outcome before age two due to severe respiratory distress.
In a murine model, ex vivo gene therapy using a lentiviral vector to transduce hematopoietic stem cells with GLB1 and transplant them into mice increased β-galactosidase enzyme activity in the central nervous system and visceral organs. This treatment significantly decreased GM1 ganglioside levels in the brain, especially in the cerebrum, rectified astrocytosis in the cerebrum, and improved motor function deficits. Secondary transplantation showed elevated serum β-galactosidase activity, suggesting long-term repopulation by transduced hematopoietic stem cells. The authors state these data indicate ex vivo gene therapy with lentiviral vectors is a promising approach for treating brain deficits in GM1 gangliosidosis.
A 1996 study comparing canine and human β-galactosidase genes found 86% identity between partial canine cDNA and human cDNA, and conservation of exon number and size. Northern blotting showed a single 2.4 kb mRNA in fibroblasts and liver from normal dogs and dogs affected with GM1 gangliosidosis. The authors concluded that canine GM1 gangliosidosis is a suitable animal model of the human disease and should further efforts to devise a gene therapy strategy.
No therapy has been shown to alter the course of GM1 gangliosidosis type 1 in humans. The gene therapy data come only from mice, and no human trial results are reported in these abstracts. What is missing is funding for clinical trials, a feasible delivery method for the central nervous system in human infants, and patient stratification by residual enzyme activity or genotype to identify who might benefit.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Molecular Therapy — Methods & Clinical Development · 2022 · 9 citations · open access
Hematopoietic stem cell gene therapy ameliorates CNS involvement in murine model of GM1-gangliosidosis
AbstractGM1-gangliosidosis is a progressive neurodegenerative glycosphingolipidosis resulting from a GLB1 gene mutation causing a deficiency of the lysosomal enzyme β-galactosidase, which leads to the abnormal accumulation of GM1 ganglioside in the central nervous system. In the most severe early infantile phenotype, excessive ganglioside accumulation results in a rapid decline in neurological and psychomotor functions, and death occurs within 2 years of age. Currently, there is no effective therapy for GM1-gangliosidosis. In this study, we evaluated the therapeutic efficacy of ex vivo gene therapy targeting hematopoietic stem cells using a lentiviral vector to increase enzyme activity, reduce substrate accumulation, and improve astrocytosis and motor function. Transplanting GLB1-transduced hematopoietic stem cells in mice increased β-galactosidase enzyme activity in the central nervous system and visceral organs. Specifically, this gene therapy significantly decreased GM1 ganglioside levels in the brain, especially in the cerebrum. More important, this gene therapy rectified astrocytosis in the cerebrum and improved motor function deficits. Furthermore, the elevation of serum β-galactosidase activity in secondary-transplanted mice suggested the ability of transduced hematopoietic stem cells to repopulate long term. These data indicate that ex vivo gene therapy with lentiviral vectors is a promising approach for the treatment of brain deficits in GM1 gangliosidosis.
American Journal of Medical Genetics · 1996 · 6 citations
Comparison of the canine and human acid β-galactosidase gene
AbstractSeveral canine cDNA libraries were screened with human beta-galactosidase cDNA as probe. Seven positive clones were isolated and sequenced yielding a partial (2060 bp) canine beta-galactosidase cDNA with 86% identity to the human beta-galactosidase cDNA. Preliminary analysis of a canine genomic library indicated conservation of exon number and size. Analysis by Northern blotting disclosed a single mRNA of 2.4 kb in fibroblasts and liver from normal dogs and dogs affected with GM1 gangliosidosis. Although incomplete, these results indicate canine GM1 gangliosidosis is a suitable animal model of the human disease and should further efforts to devise a gene therapy strategy for its treatment.
Balkan Medical Journal · 2022 · 2 citations · open access
Single Institutional Experience with GM1 Gangliosidosis: Clinical and Laboratory Results of 14 Patients
AbstractBackground: gene. Neurodegeneration, hypotonia, visceromegaly, macular cherry-red spots, skeletal dysplasia, and coarse and dysmorphic face are the major clinical features. Aims: To evaluate the demographic and clinical data of patients with GM1 gangliosidosis in a single center. Study Design: A retrospective clinical study. Methods: This study included patients followed at Hacettepe University İhsan Doğramacı Children’s Hospital Pediatric Metabolism Unit with the diagnosis of GM1 gangliosidosis between 1988 and 2021. Hospital records of the patients were reviewed for demographic, clinical, and laboratory findings. Results: < 0.05). Conclusion: Median survival in patients with GM1 gangliosidosis is less than 24 months. Beta-galactosidase enzyme activity may be associated with clinical onset and time of diagnosis in these patients.
International Journal of Contemporary Pediatrics · 2015 · 0 citations · open access
Large Mongolian spots in GM1 gangliosidosis
AbstractA 9-month old male child with GM1 gangliosidosis type 1 presented with Mongolian spots. The cutaneous lesions were present since birth before the appearance of the other features of the disease. Our patient, whose clinical course and physical signs were in keeping with GM1 gangliosidosis, had extensive Mongolian blue spots and this adds to the evidence supporting such an association.
Arquivos de Neuro-Psiquiatria · 1987 · 0 citations · open access
GM1 - type 1 glanglio sido sis: anatomo-clinic study of a case
AbstractThe observation of generalized GM1 gangliosidosis type 1 (Norman-Landing disease) is reported. The case is typical, featuring all the main clinical and biological signs of the disease. Diagnosis was established by the demonstration of a severe deficit in beta-galactosidase activity in leucocytes, by the demonstration of oligosaccharides in the urine, and by the histological examination after the fatal outcome before the age of two with severe respiratory distress.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
